Your browser doesn't support javascript.
New-onset and relapse of nephrotic syndrome following COVID-19 vaccination: a questionnaire survey in Japan.
Nakagawa, Naoki; Maruyama, Shoichi; Kashihara, Naoki; Narita, Ichiei; Isaka, Yoshitaka.
  • Nakagawa N; Joint Research Team from Japanese Society of Nephrology and the Progressive Renal Diseases Research, Research on Intractable Disease, from the Ministry of Health, Labour and Welfare of Japan, Special Study Group for Nephrotic Syndrome, Tokyo, Japan. naka-nao@asahikawa-med.ac.jp.
  • Maruyama S; Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, 2-1-1-1 Midorigaoka-higashi, Asahikawa, Japan. naka-nao@asahikawa-med.ac.jp.
  • Kashihara N; Joint Research Team from Japanese Society of Nephrology and the Progressive Renal Diseases Research, Research on Intractable Disease, from the Ministry of Health, Labour and Welfare of Japan, Special Study Group for Nephrotic Syndrome, Tokyo, Japan.
  • Narita I; Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Isaka Y; Joint Research Team from Japanese Society of Nephrology and the Progressive Renal Diseases Research, Research on Intractable Disease, from the Ministry of Health, Labour and Welfare of Japan, Special Study Group for Nephrotic Syndrome, Tokyo, Japan.
Clin Exp Nephrol ; 26(9): 909-916, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-1844393
ABSTRACT

BACKGROUND:

Recent clinical reports indicate a correlation between new-onset and relapse of nephrotic syndrome (NS) following coronavirus 2019 (COVID-19) vaccination in patients with glomerular diseases. However, there are no reports of a nationwide survey on NS following COVID-19 vaccination in Japan.

METHODS:

We conducted a web-based survey of council members of the Japanese Society of Nephrology (581 members, 382 facilities) to elucidate the relationship between COVID-19 vaccination and new-onset and relapse of NS.

RESULTS:

Following COVID-19 vaccination, 27 patients (male 15, 55.6%) with new-onset (n = 6) and relapse (n = 21) of NS were reported. Of them, 12 (44.4%) patients were diagnosed with minimal change disease at the occurrence of NS. Five patients developed a slight increase in serum creatinine levels; however, none progressed to severe renal dysfunction.

CONCLUSION:

Our findings clarify the clinical features of new-onset and relapse of NS following COVID-19 vaccination. Although there was no obvious progression to severe renal dysfunction, clinicians and pathologists should be aware that NS is a potential adverse effect of the vaccines.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Nephrotic Syndrome Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans / Male Country/Region as subject: Asia Language: English Journal: Clin Exp Nephrol Journal subject: Nephrology Year: 2022 Document Type: Article Affiliation country: S10157-022-02231-y

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Nephrotic Syndrome Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans / Male Country/Region as subject: Asia Language: English Journal: Clin Exp Nephrol Journal subject: Nephrology Year: 2022 Document Type: Article Affiliation country: S10157-022-02231-y